Skip to main content
OpenTrials
Completed

NCT Number: NCT05119413

Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma

Kligman's trio remains the gold standard treatment for melasma. It contain hydroquinone which is an effective anti-melanogenic compound but that has poor tolerance and numerous side-effects. Thiamidol has been proven to be at least as effective as hydroquinone and has a very good safety profile. The objective of this study is to compare the Kligman's trio to the same preparation in which hydroquinone is replaced by thiamidol.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Melanosis Hyperpigmentation Pigmentation Disorders Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

CHU de Nice

Nice, Alpes-maritimes, 06200, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • SIGNED WRITTEN CONSENT 1) Melasma clinically diagnosed

Exclusion criteria

  • Pregnant woman
  • Other pigmentary disorder affecting the face
  • Use of systemic or topical steroids or retinoids, use of topical depigmenting agents or depigmenting procedure in the month before the inclusion

Treatment and study plan

New trio de Kligman

Drug

Once daily application in addition to the same sunscreen

Trio Kligman

Drug

Once daily application in addition to the same sunscreen

Primary outcomes

  1. The melasma's type

    Time frame: at 12 weeks

    Clinical score MASI

Secondary outcomes

  1. the Quality of life of patient

    Time frame: at 12 weeks

    descriptive name of scale : meslascol

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nice

Other

Registry information

Official study title

Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma: a Double Blind Prospective Randomzed Study

Acronym: Kligman

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Nov 15, 2021
Registry last updated
Mar 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.